This is a working overview of Metabolite, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-18 and is reviewed periodically as new material appears.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Because polypeptide hormones are not fat-soluble, they cannot penetrate cell membranes. Thus, GH exerts some of its effects by binding to receptors on target cells, where it activates the MAPK/ERK pathway. Through this mechanism GH directly stimulates division and multiplication of chondrocytes of cartilage. GH also stimulates, through the JAK-STAT signaling pathway, the production of insulin-like growth factor 1 (IGF-1, formerly known as somatomedin C), a hormone homologous to proinsulin. The liver is a major target organ of GH for this process and is the principal site of IGF-1 production. IGF-1 has growth-stimulating effects on a wide variety of tissues. Additional IGF-1 is generated within target tissues, making it what appears to be both an endocrine and an autocrine/paracrine hormone. IGF-1 also has stimulatory effects on osteoblast and chondrocyte activity to promote bone growth. In addition to increasing height in children and adolescents, growth hormone has many other effects on the body:
Among the 16 genes, the analysis identified two for which rare mutations are known to cause monogenic obesity: MC4R and PCSK1 (proprotein convertase subtilisin/kexin type 1). One study provides genetic evidence linking rare coding variation to BMI and obesity-related phenotypes. MC4R gene mutations are associated with early-onset severe obesity. The effect of two exemplary heterozygous coding variants in the MC4R gene (C293R and S94N) are: • Rapid weight gains from early age (the most important feature). • Development of severe obesity (BMI ≫97th percentile) at early ages, usually <3 years of age. • Persistent food-seeking behavior, mostly reported from six months of age. • Parental/siblings anthropometric data: suspect if relatives present normal anthropometric data. • Tall stature/increased growth velocity (MC4R monogenic diabetes). There is limited treatment options for the most common form of monogenic obesity, MC4R mutations symptoms can be treated with a Glucagon-like Peptide-1 Receptor Agonist liraglutide which cause weight loss by reducing appetite. They found that the effects of liraglutide 3.0 mg daily for 16 weeks causes weight reducing and glucose lowering and may be relevant treatment in the most common form of monogenic obesity.
Boyer, P.D., Lardy, H. and Myrback, K. (Eds.), The Enzymes, 2nd ed., vol. 7, Academic Press, New York, 1963, p. 85-96. Brosemer RW, Kuhn RW (1969). "Comparative structural properties of honeybee and rabbit alpha-glycerophosphate dehydrogenases". Biochemistry. 8 (5): 2095–105. doi:10.1021/bi00833a047. PMID 4307630. O'Brien SJ, MacIntyre RJ (1972). "The -glycerophosphate cycle in Drosophila melanogaster. I Biochemical and developmental aspects". Biochem. Genet. 7 (2): 141–61. doi:10.1007/BF00486085. PMID 4340553. S2CID 22009695. Warkentin DL, Fondy TP (1973). "Isolation and characterization of cytoplasmic L-glycerol-3-phosphate dehydrogenase from rabbit-renal-adipose tissue and its comparison with the skeletal-muscle enzyme". Eur. J. Biochem. 36 (1): 97–109. doi:10.1111/j.1432-1033.1973.tb02889.x. PMID 4200180. Albertyn J, van Tonder A, Prior BA (1992). "Purification and characterization of glycerol-3-phosphate dehydrogenase of Saccharomyces cerevisiae". FEBS Lett. 308 (2): 130–2. Bibcode:1992FEBSL.308..130A. doi:10.1016/0014-5793(92)81259-O. PMID 1499720. S2CID 39643279. Koekemoer TC, Litthauer D, Oelofsen W (1995). "Isolation and characterization of adipose tissue glycerol-3-phosphate dehydrogenase". Int. J. Biochem. Cell Biol. 27 (6): 625–32. doi:10.1016/1357-2725(95)00012-E. PMID 7671141.
Sources: en.wikipedia.org
In 1962, Meurgues' work came to the attention of the botanist Roger Heim. He tasked her with setting up a scientific laboratory in the Muséum national d'histoire naturelle, dedicated to new methods of conservation and presentation of natural history museum collections. This included conservation techniques such as freeze-drying, and resinous injections, the scientific preservation of colours and pigments, as well as improving the interpretation of exhibitions and displays. She organised and directed the laboratory whilst studying for a Diplôme d'études approfondies (Master's degree) in zoology on Calliphoridae, (types of flies) which she completed in 1973. She was promoted to become the museum's assistant professor, and went on collecting expeditions to Kurdistan, Afghanistan, Kashmir, China, Morocco amongst others. Meurgues organised a number temporary exhibitions including: Les pigments végétaux (Vegetable Pigments) in 1963, Orchidées et plantes épiphytes (Orchids and epiphytic plants) in 1966, Météorites, messagères du cosmos (Meteorites, messengers of the cosmos) in 1968, La Nature au microscope électronique (Nature under an electron microscope) in 1971, Le Sahara avant le désert (The Sahara before the desert) in 1974, Les plus beaux coquillages du monde (The most beautiful shells of the world) in 1975, Histoire naturelle de la sexualité (Natural history of sexuality) in 1977 with André Langaney, a leading French science communicator.
=== Byproduct === The production of polonium-210 is a downside to reactors cooled with lead-bismuth eutectic rather than pure lead. However, given the eutectic properties of this alloy, some proposed Generation IV reactor designs still rely on lead-bismuth.
=== Diabetes and pregnancy === A total review of metformin use during pregnancy compared to insulin alone found good short-term safety for both the mother and baby, but safety in the longer term is unclear. Several observational studies and randomized controlled trials found metformin to be as effective and safe as insulin for the management of gestational diabetes. Nonetheless, several concerns have been raised and evidence on the long-term safety of metformin for both mother and child is lacking. Compared with insulin, women with gestational diabetes treated with metformin gain less weight and are less likely to develop pre-eclampsia during pregnancy. Babies born to women treated with metformin have less visceral fat, and this may make them less prone to insulin resistance in later life. The use of metformin for gestational diabetes resulted in smaller babies compared to treatment with insulin. However, despite initially lower birth weight, children exposed to metformin during pregnancy had accelerated growth after birth, and were heavier by mid-childhood than those exposed to insulin during pregnancy. This pattern of initial low birth weight followed by catch-up growth that surpasses comparative children has been associated with long-term cardiometabolic disease. A systematic review and meta-analysis of metformin, published in 2024, found that it is safe and effective in managing gestational diabetes or diabetes in pregnancy with no adverse impact on the mother or the child after eleven years of childbirth.
== External links == Eukaryotic Linear Motif resource motif class TRG_NLS_Bipartite_1 Eukaryotic Linear Motif resource motif class TRG_NLS_MonoCore_2 Eukaryotic Linear Motif resource motif class TRG_NLS_MonoExtC_3 Eukaryotic Linear Motif resource motif class TRG_NLS_MonoExtC_4
Sources: en.wikipedia.org
=== Epigenetics === p53 function is also influenced by chromatin environment. The corepressor TRIM24 restricts p53 binding to epigenetically repressed loci by recognizing methylated histones. This interaction enables p53 to interpret local chromatin context and regulate gene expression in a locus-specific manner.
Seeded 13th, he earned his first victory over Alexander Bublik by beating him in the first round in three sets. In the second round, he defeated world No. 29, Roberto Bautista Agut, in the second round. In the third round, he lost to third seed, Daniil Medvedev, despite serving for the match twice and having two match points in the third-set tie-break. This defeat was his seventh out of the last eight matches played with Medvedev. Seeded third at the BMW Open in Munich, he was defeated in the second round by Christopher O'Connell. Seeded 13th at the Madrid Open, he recorded his 350th career win by defeating Roberto Carballés Baena in the second round, becoming the only player under 30 to reach this milestone. In the third round, he overpowered qualifier, Hugo Grenier, in 55 minutes. In the fourth round, he lost to top seed, world No. 2, defending champion, and eventual champion, Carlos Alcaraz, in a rematch of the previous year's final. Failing to defend his finalist points from last year, his ranking fell from 16 to 22. Seeded 19th at the Italian Open, he made it to the fourth round where he lost to third seed and eventual champion, Daniil Medvedev. Having made the semifinals last year, his ranking again fell, this time from 22 to 27. Seeded third at the Geneva Open, he reached the semifinal where he lost to Nicolás Jarry, who would end up winning the tournament. Seeded 22nd at the French Open, he defeated Lloyd Harris, Alex Molčan, 12th seed Frances Tiafoe, and 28th seed Grigor Dimitrov in his first four rounds. In the quarterfinals, he faced Tomás Martín Etcheverry.
After the Polish–Russian Treaty of Andrusovo split Ukraine along the Dnieper River in 1667, Ukrainian Cossacks were known as Left-bank and Right-bank Cossacks. The ataman had executive powers, and in wartime was the supreme commander in the field. Legislative power was given to the Band Assembly (Rada). The senior officers were called starshyna. In the absence of written laws, the Cossacks were governed by the "Cossack Traditions" – the common, unwritten law. Cossack society and government were heavily militarized. The nation was called a host (vois'ko, or viys'ko, translated as "army"). The people and territories were subdivided into regimental and company districts, and village posts (polky, sotni, and stanytsi). A unit of a Cossack troop could be called a Kurin. Each Cossack settlement, alone or in conjunction with neighboring settlements, formed military units and regiments of light cavalry or, in the case of Siberian Cossacks, mounted infantry. They could respond to a threat on very short notice. A high regard for education was a tradition among the Cossacks of Ukraine. In 1654, when Macarius III Ibn al-Za'im, the Patriarch of Antioch, traveled to Moscow through Ukraine, his son, Deacon Paul Allepscius, wrote the following report:
This phenomenon was used in the design of light meters and similar devices. Selenium's semiconductor properties found numerous other applications in electronics. The development of selenium rectifiers began during the early 1930s, and these replaced copper oxide rectifiers because they were more efficient. These lasted in commercial applications until the 1970s, following which they were replaced with less expensive and even more efficient silicon rectifiers. Selenium came to medical notice later because of its toxicity to industrial workers. Selenium was also recognized as an important veterinary toxin, which is seen in animals that have eaten high-selenium plants. In 1954, the first hints of specific biological functions of selenium were discovered in microorganisms by biochemist, Jane Pinsent. It was discovered to be essential for mammalian life in 1957. In the 1970s, it was shown to be present in two independent sets of enzymes. This was followed by the discovery of selenocysteine in proteins. During the 1980s, selenocysteine was shown to be encoded by the codon UGA. The recoding mechanism was worked out first in bacteria and then in mammals (see SECIS element).
Neurofibrillary tangles in Alzheimer's disease Lewy body in Parkinson's disease Pick bodies in Pick's disease Inclusions in motor neuron disease and Huntington's disease Mallory bodies in alcoholic liver disease Rosenthal fibers in astrocytes
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.